灯盏生脉胶囊治疗缺血性中风疗效的系统评价  

Systematic Evaluation of Efficacy of Erigeron Shengmai Capsule for Ischemic Stroke

作　　者：黑赏艳[1] 梁伟雄[2] 陈倢[3] 秦劭晨[1] 许玉珉 HEI Shangyan LIANG Weixiong CHEN Jie QIN Shaochen XU Yumin(Guangzhou University of Chinese Medicine, Guangzhou 510403, Guangdong, China DME Center of Guangzhou University of Chinese Medieine,Guangzhou 510403 ,Guangdong,China The Second People＇s Hospital of Guangdong, Guangzhou 510310, Guangdong, China)

机构地区：[1]广州中医药大学,广东广州510403 [2]广州中医药大学DME中心,广东广州510403 [3]广东省第二人民医院,广东广州510310

出　　处：《辽宁中医杂志》2017年第10期2032-2037,共6页Liaoning Journal of Traditional Chinese Medicine

基　　金：国家重大新药创制专项-中药新药临床试验技术平台研究(2012ZX09303009-003)

摘　　要：目的:系统评价灯盏生脉胶囊治疗缺血性中风的疗效。方法:检索Pubmed、中国知网、维普数据库、万方数据库等,全面检索灯盏生脉胶囊治疗缺血性中风的随机对照试验,进行文献筛选、数据提取及方法学质量评价,采用Review Manager 5.2软件进行Meta分析。结果:本研究纳入20个RCT,共3133名患者,Meta分析结果显示:(1)疗效方面,灯盏生脉胶囊在总有效率,中风量表评分方面优于对照组药物[RR=1.22,95%CI(1.10,1.35),P<0.05;MD=-3.85,95%CI(-5.73,-1.98),P<0.05],而在改良Rankin量表评分及Barthel指数等方面疗效相当[MD=-0.40,95%CI(-1.13,0.33),P=0.28;MD=2.57,95%CI(-11.13,16.28),P=0.71];(2)生化指标方面,灯盏生脉胶囊同传统药物相比,可改善纤维蛋白原及低密度脂蛋白等血清水平,差异具有统计学意义[MD=-1.15,95%CI(-2.05,-0.24),P<0.05;MD=-0.64,95%CI(-0.89,-0.39),P<0.05]。结论:目前临床证据表明,灯盏生脉胶囊治疗缺血性中风疗效确切。上述结果仍需高质量的随机对照试验进行客观评价。Objective：To systematically evaluate the efficacy of Erigeron Shengmai Capsule in ischemic stroke.Methods：Through searching Pubmed,China Knowledge Resource Integrated Database,VIP database,Wanfang Digital library,this study collected randomized controlled trials about Erigeron Shengmai Capsule in ischemic stroke.And these results were analyzed by Review Manager 5.2 software.Results：Twenty RCTs were included involving 3133 patients.Meta-analysis indicated that Erigeron Shengmai Capsule was better than traditional drugs in total effective rate and national institutes of health stroke scale,and the difference between two groups was statistically significant [RR=1.22,95% CI（1.10,1.35）,P〈0.05;MD=-3.85,95% CI（-5.73,-1.98）,P〈0.05].However,except for indifference in modified ranking scale score and Barthel index[MD=-0.40,95% CI（-1.13,0.33）,P=0.28;MD=2.57,95% CI（-11.13,16.28）,P=0.71].Compared with traditional drugs,Erigeron Shengmai Capsule can improve the levels of fibrinogen and low density lipoprotein[MD=-1.15,95% CI（-2.05,-0.24）,P〈0.05;MD=-0.64,95% CI（-0.89,-0.39）,P〈0.05].Conclusion：The current clinical evidence demonstrated that Erigeron Shengmai Capsule can be more effective in treating ischemic stroke.The results still need to be confirmed by more high-quality RCTs.

关 键 词：灯盏生脉胶囊 缺血性中风 系统评价 随机对照试验 

分 类 号：R285.6[医药卫生—中药学]